Compounds > cyanates
Page last updated: 2024-08-26

cyanates and laromustine

cyanates has been researched along with laromustine in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Penketh, PG; Rice, KP; Sartorelli, AC; Shyam, K1
Baumann, RP; Penketh, PG; Sartorelli, AC; Seow, HA; Shyam, K1
Pigneux, A1
Buros, CM; Gerber, SA; Klinkerch, EJ; Kraus, TJ; Rice, KP; Schleicher, TR1
Cincotta, DJ; Ghazvinian, R; He, Y; Ji, W; Li, Y; Min, W; Praggastis, A; Rice, KP; Yang, M; Zhou, HJ1
Baumann, RP; Finch, RA; Penketh, PG; Ratner, ES; Sauro, R; Shyam, K1

Reviews

1 review(s) available for cyanates and laromustine

ArticleYear
Laromustine, a sulfonyl hydrolyzing alkylating prodrug for cancer therapy.
    IDrugs : the investigational drugs journal, 2009, Volume: 12, Issue:1

    Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Humans; Hydrazines; Isocyanates; Middle Aged; Neoplasms; Prodrugs; Sulfonamides

2009

Other Studies

5 other study(ies) available for cyanates and laromustine

ArticleYear
Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNU.
    Biochemical pharmacology, 2005, May-15, Volume: 69, Issue:10

    Topics: Animals; Antineoplastic Agents; Carmustine; Enzyme Inhibitors; Glutathione; Glutathione Reductase; Humans; Hydrazines; Isocyanates; Leukemia L1210; Mice; Prodrugs; Sulfonamides

2005
The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation.
    Oncology research, 2005, Volume: 15, Issue:6

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biotransformation; Cell Line; Cells, Cultured; CHO Cells; Cricetinae; Drug Synergism; Guanine; HL-60 Cells; Humans; Hydrazines; Isocyanates; O(6)-Methylguanine-DNA Methyltransferase; Prodrugs; Sulfonamides; Transfection

2005
Thioredoxin reductase is inhibited by the carbamoylating activity of the anticancer sulfonylhydrazine drug laromustine.
    Molecular and cellular biochemistry, 2012, Volume: 370, Issue:1-2

    Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Carbamates; Carmustine; Cell Line, Tumor; Cysteine; Drug Screening Assays, Antitumor; Hydrazines; Hydrogen-Ion Concentration; Isocyanates; Mice; Molecular Sequence Data; Peptides; Rats; Sulfonamides; Tandem Mass Spectrometry; Thioredoxin-Disulfide Reductase; Time Factors

2012
Carbamoylating activity associated with the activation of the antitumor agent laromustine inhibits angiogenesis by inducing ASK1-dependent endothelial cell death.
    PloS one, 2014, Volume: 9, Issue:7

    Topics: Animals; Antineoplastic Agents; Biocatalysis; Carbamates; Cattle; Cell Death; Cells, Cultured; Endothelial Cells; Humans; Hydrazines; Immunoblotting; Isocyanates; MAP Kinase Kinase Kinase 5; Mitogen-Activated Protein Kinase 8; Neovascularization, Physiologic; Signal Transduction; Sulfonamides; Thioredoxin Reductase 1; Thioredoxins

2014
pH-dependent general base catalyzed activation rather than isocyanate liberation may explain the superior anticancer efficacy of laromustine compared to related 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine prodrugs.
    Chemical biology & drug design, 2018, Volume: 91, Issue:1

    Topics: Animals; Antineoplastic Agents; Catalysis; Cell Line, Tumor; DNA; Drug Design; Female; Half-Life; Humans; Hydrazines; Hydrogen-Ion Concentration; Isocyanates; Leukemia; Mice; Prodrugs; Protein Carbamylation; Sulfonamides; Transplantation, Homologous

2018